France In Vivo Cro Market Size & Outlook, 2024-2030
Related Markets
France in vivo cro market highlights
- The France in vivo cro market generated a revenue of USD 230.2 million in 2023 and is expected to reach USD 399.6 million by 2030.
- The France market is expected to grow at a CAGR of 8.2% from 2024 to 2030.
- In terms of segment, small molecule was the largest revenue generating modality type in 2023.
- Large Molecule is the most lucrative modality type segment registering the fastest growth during the forecast period.
In vivo cro market data book summary
| Market revenue in 2023 | USD 230.2 million |
| Market revenue in 2030 | USD 399.6 million |
| Growth rate | 8.2% (CAGR from 2023 to 2030) |
| Largest segment | Small molecule |
| Fastest growing segment | Large Molecule |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Small Molecule, Large Molecule |
| Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Other key industry trends
- In terms of revenue, France accounted for 5.0% of the global in vivo cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany in vivo cro market is projected to lead the regional market in terms of revenue in 2030.
- Spain is the fastest growing regional market in Europe and is projected to reach USD 328.5 million by 2030.
Small molecule was the largest segment with a revenue share of 63.64% in 2024. Horizon Databook has segmented the France in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
France is anticipated to exhibit rapid growth owing to the increasing number of preclinical studies in the country. Increasing outsourcing activities, availability of skilled professionals, and low labor & manufacturing cost are some factors driving the in vivo CRO market growth.
Rising investment in R&D by pharmaceutical & biotech companies operating in France is another factor propelling the growth in the country. Furthermore, the presence of several academic institutes in the country facilitates R&D activities, driving market growth.
Institute Pasteur is a notable example, which provides a conducive environment for researchers and ensures adherence to ethical and regulatory standards when using animal models.
The institution’s Center for Animal Resources and Research (C2RA) boasts state-of the-art infrastructure that facilitates the development of innovative models for studying human diseases. In addition, the C2RA offers specialized expertise in genetically engineering rodents, enhancing its capabilities in this area.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
In Vivo CRO Market Scope
In Vivo CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
France in vivo cro market size, by modality type, 2018-2030 (US$M)
France In Vivo CRO Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
